Blog | InSphero
July 30, 2019

Are Animal NASH models slowing us down?

InSphero Senior Application Scientist Sue Grepper explains why critical limitations of dietary and genetically modified rodent models for NASH may be slowing down drug discovery efforts in this blog.  She […]
July 17, 2019

Can we really find a cure for NASH without the scalability of in vitro NASH models?

InSphero CEO Jan Lichtenberg and renowned liver disease expert Dr. Scott Friedman of the Icahn School of Medicine at Mount Sinai recently talked to PharmaExec magazine about how to resolve […]
July 11, 2019

Developing a multi-tissue platform for advanced embryotoxicity testing

InSphero’s Akura™ technology platforms team worked with Professor Andreas Hierlemann’s Bioengineering Laboratory at ETH Zürich to develop a microfluidic hanging drop system to assess metabolic competence in developmental toxicity assays.  […]
July 10, 2019

Disruptive 3D Cell Technology Drives Innovative Diabetes R&D at ADA2019

InSphero CEO Jan Lichtenberg reflects on ADA2019 and how InSphero is enabling T1D and T2D Discovery with our 3D InSight™ Diabetes Discovery Platform. Over the past few years, diabetes discovery […]
September 28, 2018

Understanding Microfluidics: the Technology Behind Body-on-a-Chip Systems

Microfluidic chips enable researchers to manipulate, image, and analyze small tissue constructs under optimal culturing conditions. Microfluidics, the technology behind emerging #body-on-a-chip and #organs-on-chips systems, is poised to transform the […]
August 20, 2018

Can 3D in vitro models deliver what pharma needs for NASH and Fibrosis drug discovery?

Pharma companies racing to develop new drugs to combat chronic liver diseases, such as NASH and fibrosis, need better preclinical testing tools for compound screening and mechanistic studies. Here’s how […]
July 18, 2018

Reaggregated human islets: the next gold standard in vitro model for diabetes research?

Correlating human pancreas donor characteristics with 3D InSight™ Islet Microtissue functionality confirms reaggregated islets are a robust, physiologically relevant model for diabetes research. With diabetes approaching epidemic proportions globally, there […]
June 29, 2018

Building a Better Model to Detect Mitochondrial Liabilities

InSphero and Agilent discuss the need for metabolically competent models with stable metabolic activity for mitochondrial toxicity testing in a new textbook chapter. Mitochondrial Dysfunction Caused by Drugs and Environmental […]
June 18, 2018

Why we need better preclinical models for NASH Drug Discovery

In honor of the inaugural International NASH Day, an initiative to raise awareness of nonalcoholic steatohepatitis (NASH), I thought it would be appropriate to reflect on the current status of […]
May 29, 2018

AstraZeneca and Genentech publish comprehensive evaluation of 3D spheroid hepatic cultures

Landmark study comparing 2D and 3D DILI models shows 3D InSight™ Human Liver Microtissues are a highly predictive liver toxicology model that outperforms 2D primary human hepatocytes in culture. In […]